In conclusion, patients with EML4-ALK V3 driven cancers have an unmet clinical need and the work presented here provides additional evidence that a polytherapy approach combining ALK inhibitors with, in this case, paclitaxel could be effective and reduce the potential for acquired resistance. The gene discussed is ALK; the disease is cancer.